Cart
×
Prosensa Webinar on Tuesday 21st of January
Dear all, As announced last week, Prosensa will organize a patient focused webinar on Tuesday 21st of January at 8 AM ET / 14hrs CET. Practical details required to dial […]
Prosensa Reports Initial Findings from the Further Clinical Data Analyses of Drisapersen for the Treatment of Duchenne Muscular Dystrophy
Leiden,The Netherlands,Jan. 16, 2014(GLOBE NEWSWIRE) –Prosensa Holding N.V.(NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet medical need, today announced initial findings from […]
Sarepta Therapeutics Announces Eteplirsen Demonstrates Continued Stability on Walking Test through 120 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 15, 2014– Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced data through Week 120 from Study 202, a Phase IIb open-label extension study of […]
Prosensa Patient Group Communication: Prosensa Regains Rights to Drisapersen
Dear Patient Group Representative, We are writing as we would like to share with you that as of January 12, 2014, Prosensa has regained the rights to drisapersen from GSK […]
Prosensa Regains Rights to Drisapersen From GSK and Retains Rights to All Other Programs for the Treatment of Duchenne Muscular Dystrophy (DMD)
LEIDEN, Netherlands and LONDON, Jan. 13, 2014 (GLOBE NEWSWIRE) — Prosensa Holding N.V. (Nasdaq:RNA) and GlaxoSmithKline (GSK) today announced that Prosensa has regained all rights from GSK to […]
Help Cure Duchenne Now, Donate Today
Help CureDuchenne Now! With only 5 days left in the year, CureDuchenne is doing all it can to raise the dollars needed to fund promising and innovative research to find […]
Will you help us Cure Duchenne now?
My son, Justin Paul Monastesse, was a gift and he lived with Duchenne for more than 25 years. Justin always had a great time even though it took 2 1/2 […]
Current Status of Drisapersen Studies: analyses and assessment of next steps are ongoing
Dear Patient Group Representative, On the 20th of September this year, we shared the results about our Phase III study (DMD114044) of drisapersen in boys with Duchenne Muscular Dystrophy […]
Exon Skipping as a Potential Treatment for Duplication Mutations in Duchenne
Click here for the recorded webinar: https://cc.readytalk.com/cc/playback/Playback.do?id=2lyea5 CureDuchenne has been an early and important funder of exon skipping research for Duchenne. As we gain visibility to an actual therapeutic with exon […]